Imperial College London

Professor David W. McComb

Faculty of EngineeringDepartment of Materials

Adjunct Professor
 
 
 
//

Contact

 

+44 (0)20 7594 6750d.mccomb Website

 
 
//

Location

 

Royal School of MinesSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Zhang:2019:10.1007/s12274-019-2308-9,
author = {Zhang, C and Zhang, X and Zhao, W and Zeng, C and Li, W and Li, B and Luo, X and Li, J and Jiang, J and Deng, B and McComb, DW and Dong, Y},
doi = {10.1007/s12274-019-2308-9},
journal = {Nano Research},
pages = {855--861},
title = {Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer},
url = {http://dx.doi.org/10.1007/s12274-019-2308-9},
volume = {12},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - © 2019, Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature. Triple-negative breast cancer (TNBC) is one type of the most aggressive breast cancers with poor prognosis. It is of great urgency to develop new therapeutics for treating TNBC. Based on current treatment guideline and genetic information of TNBC, a combinational therapy platform integrating chemotherapy drugs and mRNA encoding tumor suppressor proteins may become an efficacious strategy. In this study, we developed paclitaxel amino lipid (PAL) derived nanoparticles (NPs) to incorporate both chemotherapy drugs and P53 mRNA. The PAL P53 mRNA NPs showed superior properties compared to Abraxane ® and Lipusu ® used in the clinic including high paclitaxel loading capacity (24 wt.%, calculated by paclitaxel in PAL), PAL encapsulation efficiency (94.7% ± 6.8%) and mRNA encapsulation efficiency (88.7% ± 0.7%). Meanwhile, these NPs displayed synergetic cytotoxicity of paclitaxel and P53 mRNA in cultured TNBC cells. More importantly, we demonstrated in vivo anti-tumor efficacy of PAL P53 mRNA NPs in an orthotopic TNBC mouse model. Overall, these chemotherapy drugs derived mRNA NPs provide a new platform to integrate chemotherapy and personalized medicine using tumor genetic information, and therefore represent a promising approach for TNBC treatment. [Figure not available: see fulltext.].
AU - Zhang,C
AU - Zhang,X
AU - Zhao,W
AU - Zeng,C
AU - Li,W
AU - Li,B
AU - Luo,X
AU - Li,J
AU - Jiang,J
AU - Deng,B
AU - McComb,DW
AU - Dong,Y
DO - 10.1007/s12274-019-2308-9
EP - 861
PY - 2019///
SN - 1998-0124
SP - 855
TI - Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer
T2 - Nano Research
UR - http://dx.doi.org/10.1007/s12274-019-2308-9
VL - 12
ER -